Allogene Therapeutics, Inc. (ALLO): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALLO POWR Grades
- Quality is the dimension where ALLO ranks best; there it ranks ahead of 72.51% of US stocks.
- The strongest trend for ALLO is in Growth, which has been heading down over the past 177 days.
- ALLO ranks lowest in Stability; there it ranks in the 4th percentile.
ALLO Stock Summary
- The ratio of debt to operating expenses for ALLOGENE THERAPEUTICS INC is higher than it is for about just 0.44% of US stocks.
- With a price/sales ratio of 2,985.09, ALLOGENE THERAPEUTICS INC has a higher such ratio than 99.84% of stocks in our set.
- With a year-over-year growth in debt of -100%, ALLOGENE THERAPEUTICS INC's debt growth rate surpasses merely 0% of about US stocks.
- If you're looking for stocks that are quantitatively similar to ALLOGENE THERAPEUTICS INC, a group of peers worth examining would be RLAY, CRSP, IGMS, KRTX, and RXDX.
- ALLO's SEC filings can be seen here. And to visit ALLOGENE THERAPEUTICS INC's official web site, go to www.allogene.com.
ALLO Valuation Summary
- ALLO's price/sales ratio is 2985.2; this is 63414.89% higher than that of the median Healthcare stock.
- ALLO's EV/EBIT ratio has moved NA NA over the prior 54 months.
Below are key valuation metrics over time for ALLO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ALLO | 2023-03-24 | 2985.2 | 1.1 | -2.2 | -2.0 |
| ALLO | 2023-03-23 | 3002.9 | 1.1 | -2.2 | -2.0 |
| ALLO | 2023-03-22 | 2997.1 | 1.1 | -2.2 | -2.0 |
| ALLO | 2023-03-21 | 3187.2 | 1.2 | -2.3 | -2.1 |
| ALLO | 2023-03-20 | 3193.4 | 1.2 | -2.3 | -2.1 |
| ALLO | 2023-03-17 | 3264.6 | 1.2 | -2.4 | -2.2 |
ALLO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALLO has a Quality Grade of D, ranking ahead of 10.13% of graded US stocks.
- ALLO's asset turnover comes in at 0.032 -- ranking 350th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ALLO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.032 | 1 | -0.253 |
| 2021-03-31 | 0.031 | 1 | -0.240 |
| 2020-12-31 | 0.000 | NA | -0.294 |
| 2020-09-30 | 0.000 | NA | -0.328 |
| 2020-06-30 | 0.000 | NA | -0.370 |
| 2020-03-31 | 0.000 | NA | -0.395 |
ALLO Price Target
For more insight on analysts targets of ALLO, see our ALLO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $48.57 | Average Broker Recommendation | 1.42 (Moderate Buy) |
ALLO Stock Price Chart Interactive Chart >
ALLO Price/Volume Stats
| Current price | $4.94 | 52-week high | $17.49 |
| Prev. close | $4.97 | 52-week low | $4.83 |
| Day low | $4.84 | Volume | 1,940,900 |
| Day high | $5.11 | Avg. volume | 1,880,674 |
| 50-day MA | $6.43 | Dividend yield | N/A |
| 200-day MA | $9.87 | Market Cap | 713.82M |
Allogene Therapeutics, Inc. (ALLO) Company Bio
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the research, development, and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, a CAR T cell product candidate targeting CD19, which is in clinical trials in patients with R/R B-cell precursor acute lymphoblastic leukemia; ALLO-501, an allogeneic anti-CD19 CAR T cell product candidate for the treatment of patients with R/R non-Hodgkin lymphoma; ALLO-715, an allogeneic CAR T cell product candidate for the treatment of patients with R/R multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepleting agent. It is also developing ALLO-819, an anti-Flt3 product candidate for the treatment of acute myeloid leukemia; CD70 for the treatment of renal cell cancer; and DLL3 for the treatment of small cell lung cancer. The company was founded in 2017 and is based in South San Francisco, California.
Latest ALLO News From Around the Web
Below are the latest news stories about ALLOGENE THERAPEUTICS INC that investors may wish to consider to help them evaluate ALLO as an investment opportunity.
Here's Why Allogene Therapeutics (ALLO) is Poised for a Turnaround After Losing -17.44% in 4 WeeksThe heavy selling pressure might have exhausted for Allogene Therapeutics (ALLO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
7 Short-Squeeze Stocks That Could Explode in AprilAlthough these short-squeeze stocks attracted bearish attention justifiably, contrarian sentiment may see them jump higher. |
Why Is Allogene Therapeutics (ALLO) Down 19.4% Since Last Earnings Report?Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) ReportReport Highlights Company’s Mission to Democratize Patient Access to CAR T While Maintaining Focus on Employee Engagement, Sustainability and Corporate GovernanceSOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today published its 2022 annual ESG report. The report provides an update on the Company’s robust efforts to r |
Short Interest Update - Monday, March 27Although equities broadly are starting the new week higher, the most heavily shorted stocks are trading lower today. |
ALLO Price Returns
| 1-mo | -17.94% |
| 3-mo | -21.46% |
| 6-mo | -53.70% |
| 1-year | -47.72% |
| 3-year | -73.14% |
| 5-year | N/A |
| YTD | -21.46% |
| 2022 | -57.84% |
| 2021 | -40.89% |
| 2020 | -2.85% |
| 2019 | -3.53% |
| 2018 | N/A |
Loading social stream, please wait...